The CLK1/SRSF5 pathway induces aberrant exon skipping of METTL14 and Cyclin L2, which promotes growth and

metastasis and regulates m6A methylation of PDAC cells. This study suggests the potential prognostic value and

therapeutic targeting of this pathway in PDAC patients.

NTRK fusion genes are valuable diagnostic and prognostic markers.

High LC3 protein expression shows a certain prognostic value in CRC patients. LC3, the MSI status, and KRAS

mutations must be considered when selecting an adjuvant therapy for CRC. The detection of these indexes is of

great significance to identify high-risk patients who would benefit from autophagy-related anticancer drugs or help

to explore more effective treatment options for patients who are resistant to conventional chemotherapy or relapse.

Liquid biopsy screening based on highly sensitive NGS is reliable for detecting drug resistance and actionable

somatic mutations. The plasma abundance of the EGFR driver mutation affected clinical response to EGFR-TKIs in

advanced NSCLC patients; prolongation of PFS was also observed in patients with an ultra-low abundance of EGFR

sensitizing mutations.

 if patients are going to undergo TRK-based targeted therapy, only RNA-based NGS for detection of the specific

fusion could tell the precise rearrangement information.

BoM was identified as an independent inferior prognostic factor for EGFR-TKI treatment, and may have complex

biological implications.